Retatrutide Dosage & Dosing Guide

Introduction to Retatrutide

Retatrutide is an investigational triple hormone agonist developed by Eli Lilly and Company, representing a new frontier in obesity and metabolic research. Unlike traditional therapies, retatrutide is designed to simultaneously target three key metabolic pathways by activating the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This innovative approach is currently being evaluated in the TRIUMPH clinical trial program, which encompasses multiple Phase 3 trials focused on weight management for individuals with obesity and related conditions.

The ongoing studies are also exploring retatrutide’s potential benefits for patients with obstructive sleep apnea, knee osteoarthritis, and established cardiovascular disease. As part of Eli Lilly’s expanding metabolic pipeline, retatrutide is positioned to address the complex needs of patients who have not achieved adequate results with existing therapies, offering hope for improved outcomes in obesity and its associated comorbidities.

Mechanism of Action

Retatrutide’s unique mechanism of action is based on its ability to activate three distinct hormone receptors: GIP, GLP-1, and glucagon receptors. This triple agonist approach sets it apart from currently approved obesity medications, which typically target only one or two of these pathways. By engaging all three receptors, retatrutide is designed to deliver a more comprehensive metabolic effect—promoting significant weight loss and improved weight management.

Activation of GLP-1 and GIP receptors helps reduce appetite and enhance insulin secretion, while glucagon receptor stimulation increases energy expenditure and promotes fat oxidation. This synergy not only supports greater reductions in body weight but also contributes to improvements in blood pressure, fasting glucose, and other metabolic parameters. The result is a promising new option for individuals with obesity, offering the potential for significant weight loss and better control of related health risks compared to existing therapies.

What Is the TRIUMPH Clinical Trial Program Dosing Protocol?

The TRIUMPH clinical trial program is Eli Lilly’s Phase 3 evaluation of Retatrutide for obesity and metabolic research. Retatrutide’s triple-agonist mechanism — targeting GLP-1, GIP, and glucagon receptors simultaneously — underpins the trial’s dosing strategy. The dosing protocol is designed around a slow, stepwise titration that allows researchers to evaluate tolerability at each escalation level before advancing to the next dose tier. The TRIUMPH program is a pivotal study in advancing obesity research, with the potential to set new standards for efficacy and safety in metabolic therapies.

The trial design was informed by Phase 2 data published by Jastreboff et al. in the New England Journal of Medicine (2023), which demonstrated that gradual escalation significantly reduced the incidence and severity of GI-related adverse events compared to rapid dose increases. The Phase 2 study evaluated doses up to 12mg/week, while the TRIUMPH Phase 3 program extends evaluation to a 15mg/week arm.

Key features of the TRIUMPH dosing protocol:

• Initiation at 0.5mg/week for the first 4 weeks—a sub-therapeutic dose designed purely for tolerability assessment
• 4-week escalation intervals—each dose level is maintained for a full 4 weeks before the next increase
• Three target maintenance arms: 5mg, 10mg, and 15mg per week, allowing dose-response evaluation across a wide range
• Dose-hold provision: if tolerability issues arise at any escalation step, the current dose can be maintained for an additional 4-week period before retrying escalation
• Dose-reduction option: participants may return to the previous tolerated dose if the current level proves intolerable
• Dose escalation for additional weight loss: escalation to a higher dose may be considered for participants who demonstrate additional weight loss and tolerate the current dose

If a participant exhibits an inadequate response—such as insufficient weight loss after a defined treatment period—the protocol may require discontinuation or adjustment of therapy to ensure optimal outcomes.

The TRIUMPH trials are registered on ClinicalTrials.gov under identifiers NCT06490861 and NCT06490874. Retatrutide remains an investigational compound with no regulatory approval in any jurisdiction. All research use of this compound must comply with applicable local regulations.

Tolerability and protocol adherence are closely monitored, with discontinuation rates reported in clinical trials serving as important indicators of safety and overall treatment tolerability.

How Do You Calculate Click-to-Dose for the 30mg Pen?

The Remy Peptides 30mg Retatrutide pen delivers 0.1mg per click with a total of 300 clicks per pen. This provides precise, reproducible dosing for laboratory research protocols without the need for volumetric measurement or reconstitution. To determine the number of clicks required for any target dose, divide the dose in milligrams by 0.1.

At the highest maintenance dose of 15mg/week, each 30mg pen provides 2 full weeks of dosing (150 clicks used per week, 300 clicks total). At the mid-range 10mg dose, a single pen lasts 3 weeks. At the lowest maintenance dose of 5mg/week, one pen covers 6 weeks of research protocol.

The Remy 30mg pen is supplied at AED 1,200 (single pen) or AED 1,000/pen in a 5-pack research tier. A 20mg format is also available. All pens are HPLC-verified at 99.262% purity by Janoshik Analytical (Batch RETP002). For research use only.

What Is the Titration Schedule?

The following week-by-week titration schedule is derived from the published TRIUMPH Phase 3 trial design. This schedule represents the intended escalation pathway for the 15mg/week target arm—the most aggressive titration studied. Researchers targeting 5mg or 10mg maintenance will reach their target dose earlier and omit the later escalation steps.

For the 10mg/week target arm, the titration reaches maintenance at approximately week 21 following a similar stepwise escalation (0.5 → 1 → 2 → 4 → 6 → 10mg). For the 5mg/week target arm, maintenance is reached at approximately week 17 (0.5 → 1 → 2 → 3 → 5mg).

Gastrointestinal adverse events during dose escalation are partially mitigated by this gradual titration protocol, which helps improve tolerability at higher doses. Clinical trials report percent change in body weight as a primary outcome at each dose level, including the 12mg and 15mg arms, highlighting the efficacy of the escalation schedule.

These timelines assume uninterrupted escalation without dose-hold periods. If tolerability-related dose holds are required at any step, the total time to maintenance will extend by 4 weeks for each hold period. The TRIUMPH protocol permits multiple dose-hold periods if needed.

Adverse Events and Safety

The safety profile of retatrutide is being rigorously evaluated in ongoing Phase 3 trials, with a particular focus on tolerability and the management of adverse events. The most common adverse events observed in clinical research are gastrointestinal in nature, including nausea, diarrhea, and vomiting. These symptoms are generally mild and tend to occur during the initial dose escalation phases.

The TRIUMPH dosing protocol incorporates a gradual escalation strategy, allowing participants to start at a low dose and slowly increase to the maintenance dose, which helps to partially mitigate these common adverse events. If adverse events become problematic, the protocol allows for dose reduction or holding at the current dose level until symptoms resolve.

Importantly, individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are excluded from participation due to the potential risks associated with GLP-1 receptor agonists. Overall, the safety profile of retatrutide is considered manageable, with most adverse events being generally mild and rarely leading to treatment discontinuation. For a comprehensive review, see retatrutide side effects.

Patient Education and Support

Comprehensive patient education and ongoing support are essential components of successful weight loss and obesity management with retatrutide. Patients should be thoroughly informed about the expected benefits of treatment, as well as the potential for common adverse events such as gastrointestinal symptoms. Understanding the importance of gradual dose escalation and adherence to the once-weekly subcutaneous injection schedule can help minimize side effects and improve treatment outcomes.

In addition to medication, patients are encouraged to maintain a healthy lifestyle, including a reduced-calorie diet and regular physical activity, to maximize weight loss results. Healthcare providers play a critical role in monitoring patient progress, adjusting doses as needed, and addressing any concerns that arise during therapy. By fostering open communication and providing clear guidance, clinicians can help patients navigate the challenges of obesity treatment and achieve meaningful, sustained improvements in health.

What Are the Key Weight Management Research Considerations?

Researchers conducting in-vitro studies with Retatrutide should be aware of several factors documented in published clinical trial data that may inform laboratory protocol design. The following considerations are drawn from the Phase 2 results published by Jastreboff et al. (NEJM 2023) and the TRIUMPH trial design documents.

• Baseline BMI: Participant baseline BMI is a key variable in evaluating weight loss effectiveness and stratifying trial results. Baseline BMI is routinely reported in clinical trials to contextualize outcomes and safety profiles.
• GI tolerability profile: Nausea, diarrhoea, and decreased appetite were the most commonly reported adverse events in Phase 2. For a comprehensive review, see retatrutide side effects. These were predominantly mild-to-moderate in severity and most frequent during escalation phases rather than at maintenance doses. The slow titration protocol was specifically designed to mitigate this.
• Injection site considerations: Subcutaneous injection sites (abdomen, thigh, upper arm) should be rotated to minimise injection-site reactions. The Phase 2 data showed low rates of injection-site adverse events across all dose levels.
• Dose-response relationship: Phase 2 data demonstrated a clear dose-response curve, with 24.2% mean body weight reduction at the highest dose (12mg) versus 8.9% at the lowest active dose (1mg) over 48 weeks. The TRIUMPH Phase 3 extension to 15mg/week aims to determine whether additional efficacy is achievable beyond the Phase 2 range. Retatrutide has shown promise as an effective treatment for obesity and related conditions, with significant improvements in weight loss and physical function.
• Metabolic parameters and cardiovascular outcomes: Beyond weight-related endpoints, Phase 2 data showed improvements in HbA1c, fasting glucose, blood pressure, and lipid profiles. The triple-receptor mechanism—particularly glucagon receptor agonism—is hypothesised to drive hepatic lipid oxidation and energy expenditure effects not seen with GLP-1-only or dual-agonist compounds. Clinical trials have also reported cardiovascular benefits, including reductions in systolic blood pressure and improvements in lipid profiles. Retatrutide treatment is associated with reductions in markers of cardiovascular risk, such as non-HDL cholesterol and hsCRP.
• Knee pain and osteoarthritis pain: In participants with obesity and knee osteoarthritis, retatrutide has demonstrated improvements in knee pain and osteoarthritis pain, as measured by validated pain scores.
• Adverse events: Most adverse events were mild to moderate. Certain side effects, such as dysesthesia, were generally mild and rarely led to treatment discontinuation.
• Storage requirements: Retatrutide pens should be stored at 2–8°C (refrigerated) and protected from light. Once in use, pens may be kept at room temperature (below 30°C) for up to 21 days. Do not freeze. Cold-chain integrity is especially critical in the UAE climate. See our peptide storage guide for complete handling protocols.
• Pen handling: The 30mg FlexiPen requires no reconstitution. Prime with 1 click before first use to clear the needle assembly. Each subsequent click delivers exactly 0.1mg of compound. Do not use if the solution appears cloudy, discoloured, or contains particulate matter.

All Remy Peptides Retatrutide pens are supplied with a Janoshik Analytical Certificate of Analysis verifying 99.262% HPLC purity (Batch RETP002). This documentation supports laboratory quality assurance and chain-of-custody requirements for research protocols. For efficacy comparisons at these dose levels, see Retatrutide vs Tirzepatide vs CagriSema. For verified research suppliers, see our best research peptides 2026 guide.

Positive clinical trial results for retatrutide have been announced via press release by the sponsor, highlighting the significance of these findings. Retatrutide remains investigational, with FDA approval anticipated following completion of the TRIUMPH Phase 3 program and regulatory review.